We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) is a biotechnology company specializing in clinical ... read more Featured Products: More products

Download Mobile App





Snibe Diagnostic Displays Analyzers at MEDLAB Europe 2018

By LabMedica International staff writers
Posted on 04 Oct 2018
Print article
Image: Snibe showcased its latest range of chemiluminescent immunoassay analyzers at MEDLAB Europe 2018 (Photo courtesy of Snibe).
Image: Snibe showcased its latest range of chemiluminescent immunoassay analyzers at MEDLAB Europe 2018 (Photo courtesy of Snibe).
Shenzhen New Industries Biomedical Engineering Co., Ltd. {(Snibe Co. Ltd.) Shenzhen, China} showcased its latest range of chemiluminescent immunoassay analyzers at MEDLAB Europe 2018 held in Barcelona, Spain, from October 2-4, 2018.

More than 150 exhibitors showcased the latest cutting edge technologies and recent developments in the medical laboratory industry at the second edition of the show. MEDLAB Europe 2018 welcomed more than 2,600 international visitors and delegates, offering international manufacturers a chance to network with over 1,000 medical dealers and distributors from Spain, Italy, France, Germany, Portugal and other countries.

Snibe is a bio-medical company specialized in clinical laboratory instruments and in vitro diagnostic reagents. The company manufactures a range of chemiluminescent immunoassay analyzers and clinical chemistry analyzers. It has achieved several milestones, such as developing China's first automated CLIA analyzer and dedicated kits in 2008 and launching the country’s first integrated system in 2012. Snibe is also the first CLIA manufacturer in China to receive FDA clearance in 2017.

Snibe offers chemiluminescent immunoassay analyzers under the MAGLUMI series and its clinical chemistry analyzers under the Biossays series. Currently, more than 3,000 hospitals in China are using the company’s MAGLUMI CLIA system. Snibe also offers the Biolumi 8000 Integrated Lab System that combines an electrolyte module, chemistry module and immunoassay module in a single platform.


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.